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Abstract
Altered activity of the human dopamine transporter gene (hDAT) is asssociated with several
common and severe brain disorders including cocaine abuse. However, there is little a priori
information on whether such alteration was due to nature (genetic variantion) or nurture (human
behaviors such as cocaine abuse). This study investigated the correlation between seven markers
throughout hDAT and its mRNA levels in postmortem ventral midbrain tissues from 18 cocaine
abusers and 18 strictly matched drug-free controls in the African American population. Here we
show that one major haplotype with same frequency in cocaine abusers versus drug-free controls
displays a 37.1%-reduction of expression levels in cocaine abusers, compared to matched controls
(P = 0.0057). The most studied genetic marker, variable number tandem repeats (VNTR) located
in Exon 15 (3′VNTR), is not correlated with hDAT mRNA levels. A 5′ upstream VNTR
(rs70957367) has repeat numbers positively correlated with expression levels in controls (r2
0.9536, P = 0.0235) but this positive correlation disappears in cocaine abusers. The findings
suggest that varying hDAT activity is attributed to both genetics and cocaine abuse.
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INTRODUCTION
Dopamine (DA) neurotransmission regulates physiological states including motivation,
cognition, and attention, and contributes to pathological processes including substance
abuse. The human dopamine transporter (hDAT) is an important regulator of DA
neurotransmission and a target of psychostimulant drugs of abuse such as cocaine.
Conceivably, varying expression levels may be atributable to both genetic variation and
substance abuse; and abnormal expression may confer risks for the related brain disorders.
In fact, reduced hDAT expression is correlated with both aging and diseases. In humans,
decreased hDAT mRNA levels, in contrast to increased tyrosine hydroxylase (TH) mRNA
levels, are found in residual DA neurons of Alzheimer’s disease patients (Joyce et al., 1997).
Animal models show that different DAT dosages confer variations in locomotion activity
(Giros et al., 1996), cocaine reward (Sora et al., 2001) and susceptibility to
neurodegeneration in the neurotoxin MPTP models (Gainetdinov et al., 1997; Bezard et al.,
1999), consistent with the view that reduced hDAT expression may be associated with
various diseases.
In order to identify the underlying genetic risks, more than 150 association studies have
investigated association of the hDAT-encoding gene hDAT (or SLC6A3) with various
diseases. Most of the studies used markers located in the 3′ end of the gene, including the
40-bp variable number of tandem repeats located in the 3′ untranslated region (3′VNTR in
3′UTR) and more recently the 30-bp VNTR located in Intron 8 (Int8VNTR). Findings with
3′VNTR showed small effect size or are elusive for attention deficit/hyperactivity disorder
(ADHD) (Faraone and Mick, 2010) and drug abuse (van der Zwaluw et al., 2009; Lohoff et
al., 2010) among other disorders. More recently, the 6-repeat of 30-bp allele in Int8VNTR
was associated with cocaine addiction in Brazilians, smoking in a British population and
ADHD in both British and Taiwanese populations (Brookes et al., 2006; Guindalini et al.,
2006; O’Gara et al., 2007). Despite the extensive investigations and variable associations of
numerous CNS disorders with various hDAT markers, little is known about whether
different alleles or haplotypes in hDAT are correlated with differences in gene expression in
human brain tissues.
To better understand altered hDAT activity in related diseases, it is necessary to delineate the
relationship between genetic variation (nature) or environmental experience (nurture) and
gene expression in the brain. In this study, we used exonic polymorphisms to quantify
haplotypic expression of hDAT in postmortem brain tissues of cocaine abusers and the
matched drug-free control subjects.
SUBJECTS AND METHODS
Postmortem brain tissue acquisition and subject characterization
Postmortem ventral midbrain specimens were obtained during routine autopsy and analyzed
as described previously (Bannon and Whitty, 1997). Medicolegal investigations were
conducted by forensic pathologists. The cause and manner of death were determined after
evaluating the circumstances of death, toxicology data, and autopsy results. All cases were
evaluated for common drugs of abuse (including alcohol), and positive urine screens were
confirmed by quantitative analysis of blood. Blood levels of cocaine and metabolites were
determined as described before (Hernandez et al., 1994). The cocaine abuse cohort in the
present study had a documented history of drug abuse, tested positive for cocaine and/or
metabolites but negative for other drugs of abuse (except for 10B, diazepam and 13B,
methadone), and were determined to have died as a result of cocaine abuse or cocaine
intoxication. Control subjects had no documented history of drug abuse, were drug-free at
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time of death, and died as a result of cardiovascular disease, gunshot wounds, or pulmonary
embolism. Pair-wise matches of cocaine abusers and matched drug-free controls for age,
gender, and pH are summarized in Table 1. Ethnicity was defined by medical legal records.
Ventral midbrain was cut on a cryostat and the DA cell enriched area of ventral midbrain
was hand dissected from slides. There was no difference between cocaine abusers and
matched controls in pH and no effect of pH on hDAT mRNA levels.
Genomic DNA preparation
The Wizard® SV Genomic DNA Purification System (Promega, WI, USA) was used for
genomic DNA isolation: briefly, 20 mg of tissue sample or 2–4×106 cells was digested in
275 μl of Digestion Solution Master Mix or 150 μl of Wizard® SV Lysis Buffer, followed
by overnight incubation at 55°C. After the rest of the procedure, genomic DNA was
dissolved in 500 μl Elution Buffer.
Genotyping
The polymerase chain reaction (PCR)-RFLP method was used for SNPs/VNTR genotyping.
PCR followed standard protocols by using the Fast PCR Master Mix (Fermentas, MD,
USA), associated instructions and primers listed in Table S1. For 5′VNTR, the PCR product
was 426-bp, 486-bp, 546-bp, and 606-bp for 6-, 7-, 8-, and 9-repeat respectively. Int8VNTR
showed 291-bp and 321-bp for 5- and 6-repeat; 3′VNTR, 441-bp and 481-bp for 9- and 10-
repeat. These VNTR’s PCR products were subject to agarose gel electrophoresis directly for
length polymorphism. PCR products were 174-bp and 300-bp for DNPi and rs6347. The B
allele (GAGGAG), but not the A allele (GAGAGG), of DNPi (di-nucleotide polymorphisms
in Intron 1) was BseRI-sensitive for 127-bp and 47-bp digests. 300-bp of rs6347 could be
digested by BbvcI into 194-bp and 106-bp for the A allele but not for the G allele. NsiI
digested the T alleles of both rs11564775 and rs6876890 and the genotypes were identified
through electrophoresis-based length polymorphism as well.
RNA isolation
RNA was extracted from ventral midbrain tissues with TRIzol Reagent (Invitrogen, CA,
USA). RNA samples were quantified using a NanoDrop (ThermoScientific, DE, USA) and
the RNA integrity was assessed with a BioAnalyzer (Agilent Technologies, CA, USA).
There was no difference in 260/280 ratio between the drug-free control (2.04 ± 0.01) and
cocaine abuser groups (2.04 ± 0.01; P; 0.881) nor in the RNA integrity numbers (RINs;
control 6.5 ± 0.2; cocaine abuser 6.9 ± 0.1; P: 0.134) as determined by t-tests.
cDNA synthesis
To prepare cDNA, 0.5–1 μg of total DNase-treated RNA was reverse-transcribed with
Oligo(dT)20 primers by using a SuperScript cDNA synthesis system (Invitrogen). The
cDNA was either used immediately for PCR or stored at −20°C for subsequent analysis.
BStop-PCR
To quantify allelic cDNA, a modification of hot-stop PCR (Uejima et al., 2000) was made
by replacing an isotope-labeled primer with a biotin-labeled primer in the final
quantification PCR cycle and we termed this modified method as BStop-PCR. Hot-start
reactions (94°C for 5 min) were initiated with 0.4U Taq DNA polymerase (New England
Biolabs, Ipswich, MA, USA) followed by 28 cycles of amplification. Each cycle consisted
of 30 sec at 94°C, 30 sec at 63°C, and 1 min at 72°C. Elimination of heteroduplexes from
the analysis of PCR products followed the hot-stop PCR procedure. The corresponding PCR
products containing the “A” allele of rs6347 were subject to BbvcI digestion to produce 114-
bp and 26-bp fragments. After capillary transfer of DNA to a positively charged nylon
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membrane, biotin-labeled DNA was visualized by using the BrightStar BioDetect Kit
(Ambion), followed by quantification with TL100.
Quantification of mRNA levels
Quantitative real-time PCR (qRT-PCR) reactions used the SYBR Green PCR Master Mix
(Applied Biosystems, CA, USA). Data were normalized with GAPDH because GAPDH
transcript abundance did not differ between cocaine abusers and the matched controls. All
primers used in this study, prepared by Integrated DNA Technology (IDT, IA, USA), are
listed in Table S1.
Statistics
Data are expressed as mean ± SEM values. The statistical significance of differences among
groups was determined by one-way ANOVA or by Mann-Whitney U tests. Analysis of
Covariance was used to compare two line tests. Linkage disequilibrium (LD) parameters (D′
and r2) and haplotype frequencies were estimated with the Haploview 4.1 program (Barrett
et al., 2005) and SHEsis softwares (Li et al., 2009). Dandelion Version 3.0 was for
association analysis; PHASE (version 2.1) (Stephens et al., 2003) and PL-EM for haplotype
inferences (Niu, 2004).
RESULTS
Selection and linkage disequilibrium (LD) of hDAT markers
Five markers were selected to physically cover 90% (63.1 kb) of the 70 kb gene: a 5′VNTR,
DNPi, Int8VNTR (a VNTR in Intron 8), rs6347 (a single nucleotide polymorphism or SNP
in Exon 9), and the often-studied 3′VNTR in the last exon, Exon 15 or the 3′ untranslated
region (3′UTR). Two additional SNPs were typed, too, due to their proximity to 3′VNTR:
rs6876890 and rs11564775 (Figure 1). 5′VNTR and DNPi were selected because of their
high heterogeneities for potential functionality because Tajima’s D statistic was positive for
both: 2.44 (P < 0.05) and 1.26 (Drgon et al., 2006; Tajima 1989). Int8VNTR and 3′VNTR
were selected for their reported in vitro functionalities and positive associations with
diseases (Guindalini et al., 2006). rs6347 was included because of its exonic location as well
as its MAF (minor allele frequency) of > 0.2 in many populations, based on dbSNP
information. Allelic frequency information in the 36 subjects is summarized in Table 2
(genotype frequency information is provided in Table S2). Four alleles were found for
5′VNTR in this sample, two alleles for each of the two other VNTRs. All of them are highly
informative based on their high MAF values. None of the markers failed the Hardy-
Weinberg Equilibrium (HWE) tests (Table 2). Notice that 6-repeat of Int8VNTR was the
minor allele in this cohort whereas 5-repeat was the minor allele in other populations (e.g.
Guindalini et al., 2006), indicating ethnicity-related variation in allele frequency,
The 63.1 kb region from 5′VNTR to rs11564775 was not in high LD except those between
Int8VNTR and rs6347 and among the last three markers in Exon 15 (see Figure 1b upper
panel). LD was medium between 3′VNTR and DNPi (D′ = 0.12 by Haploview or 0.59 by
SHEsis) or 5′VNTR (D′ = 0.25). 5′VNTR and DNPi displayed medium level of LD (D′
0.42) while Int8VNTR and rs6347 displayed strong LD (D′ 0.57 by Haploview or 0.90 by
SHEsis). LD in the matched controls differed slightly from that in the cocaine abusers
(Figure 1b lower panels).
Reduced expression of a major hDAT haplotype in cocaine abusers
The 36 subjects used here were strictly paired between controls and cocaine abusers in race,
age and gender (Table 1). The 18 cocaine abusers tended to have decreased expression
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(18.9%) without reaching any statistical significance, comparing to the controls. A total of
27 haplotypes were inferred statistically from the seven polymorphisms for the 36 subjects.
Controls carried eight unique haplotypes and abusers carried ten unique haplotypes, sharing
nine haplotypes.
Analysis of correlation between haplotypes and expression levels revealed that one of the
haplotypes, B5G10TC that covered the last six polymorphisms (frequency: 0.33 in drug-free
controls versus 0.31 cocaine abusers) displayed an average expression level 37.1% less in
cocaine abuser carriers than in control carriers (P = 0.005672 by Mann-Whitney U tests,
Figure 2a). This B5G10TC-mediated reduction contributed to the overall small decrease
(Figure 2b) because the rest of the haplotypes did not display any reduced expression in the
abusers (Figure 2c). In drug-free controls, the B5G10TC activity remained the averages of
other haplotypes combined.
Haplotype-dependent hDAT expression in human brain: lack of correlation between 3′
markers and mRNA levels
We next went on to use both exonic markers rs6347 and 3′VNTR to assess allelic hDAT
expression in human midbrain samples by BStop-PCR, making sure of high degree of
confidence in the expression data and increasing the use of available samples. BStop-PCR
used biotin as the labeling signal, which displayed good dynamics (Figure S1). Among the
36 subjects, 18 carried informative (or both alleles) rs6347, 11 carried informative 3′VNTR
and 6 carried both. Among the 18 rs6347-carriers, 13 (61.1%) displayed allelic dependence
(> 1.2-fold allelic difference for statistical significance) of hDAT expression. The average
ratio of G/A is 1.027 ± 0.095-fold for all 18 subjects and 1.023 ± 0.156-fold among the 11
subjects (Figure 3a), suggesting that neither of the alleles are consistently associated with
higher expression. Similarly among the 11 3′VNTR-carriers, five (45.5%) displayed allelic
dependence (> 1.2-fold allelic difference). The average ratio of 10/9 is 0.983 ± 0.111-fold
for all 11 samples and 0.924 ± 0.252-fold among the five subjects that displayed allelic
dependence (Figure 3b), again suggesting that neither of the alleles are consistently
associated with higher expression. The corresponding haplotypes in each subject are
indicated on the right side of both graphs, showing that none of the alleles of typed markers
are consistently associated with a high or low ratio.
Approximately 42% of the controls (3/8 by rs6347 and 2/4 by 3′VNTR) and 47% of the
abusers (4/10 by rs6347 and 4/7 by 3′VNTR) did not show any haplotype-dependence of
expression (ratio ~1). Overall the allelic or haplotype-dependence of hDAT expression was
very significant, as the ANOVA P value is < 0.0001 based on both markers. The data from
the two markers are generally consistent with each other with a linear regression coefficient
(r2) of 0.9468 (P: 0.0011) in six individuals that carried both markers.
The next question was whether the allelic or haplotype-dependence is correlated with overall
hDAT expression in 24 informative individuals (those carried at least one of the two exonic
markers). To address this question, we have analyzed the hDAT mRNA levels by qRT-PCR.
The results show that allelic dependence of rs6347 correlates positively with the mRNA
levels (r2: 0.3824 for goodness of fit, P: 0.0062 for non-zero linearity, see Figure 3c). We
failed to find such correlation for the 3′VNTR marker (Figure 3d). We postulate that rs6347
was on the same background as other functional polymorphisms such as the nearby
Int8VNTR and haplotypes of the upstream promoter (Greenwood and Kelsoe 2003; Kelada
et al, 2005; Hill et al, 2010). However, 3′VNTR is located further away from those
functional variants with weak LD (Figure 1a).
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Positive correlation of 5′VNTR with hDAT mRNA levels
Delineation of allelic expression may lead to identification of new markers for association
study or generating functionality hypotheses to test. We first looked at 5′VNTR because this
could be a new risk locus. The subjects were stratified by drug phenotypes because cocaine
abuse could confound a potential correlation. The total repeat number in each drug-free
control can be positively correlated with the average hDAT mRNA levels (Figure 4a, b).
However, this positive correlation was not observed, not even for the averages, in the
cocaine abusers (Figure 4c, d). We summed the repeats on both chromosomes and correlated
the sum with the mRNA level attributed to both chromosomes because if a transcription
factor binds to a repeat sequence for functional effect, multiple bindings would increase the
additive effect.
By contrast, alleles for Int8VNTR (Figure S2) and 3′VNTR (Figure S3) or the VNTR
haplotype 6–10 (Figure S4) display no significant correlation with the expression levels. No
correlation was found for other markers either.
DISCUSSION
This study assessed the correlation of hDAT haplotypes with corresponding transcript
abundance in human midbrain. We demonstrated that hDAT expression is clearly haplotype-
dependent and furthermore that the dependence varies by a large range in human midbrain
tissues. In particular, this study discovered that B5G10TC, a main African American
haplotype with the same frequency in drug-free controls versus cocaine abusers, displays
reduced expression in cocaine abusers, comparing to drug-free controls. Among the
examined markers, 5′VNTR is the only marker that correlates positively with mRNA levels
in drug-free controls but not in cocaine abusers. These preliminary but intriguing findings
could imply hDAT epigenetic effects that warrant further investigation.
Markers for future association study
The observed low LD between the major regulatory regions such as 5′ promoter, Intron 8
and 3′UTR was consistent with previous findings especially in American samples
(Guindalini et al., 2006; Greenwood et al., 2006). Such LD information suggests that
genotype data with the Int8VNTR or 3′VNTR would not be able to reflect the 5′promoter
activity variation and vice versa, as postulated in the results. For cocaine abuse, both 5′ and
Intron 8-3′ ends could confer risk. Although previous studies have shown that 3′VNTR and
Int8VNTR can regulate expression of a reporter gene in vitro (Inoue-Murayama et al., 2002;
Miller and Madras, 2002; Hill et al., 2010), neither correlate with mRNA levels in human
brain tissues in this study.
Because of the low LD, all three VNTRs should be evaluated for substance abuse. This
notion is supported by findings for other diseases. For example, markers in upstream regions
displayed more consistent positive signals than 3′VNTR for associations with schizophrenia
and bipolar disorders (Khodayari et al., 2004; Stöber et al., 2006; Serretti and Mandelli,
2008; Talkowski et al., 2008).
Regulatory haplotypes in cocaine abusers
B5G10TC is a major African American haplotype of the transcribed region and has same
frequency in drug-free controls versus cocaine abusers. Based on reported findings that low
activity-associated alleles such as 6-repeat of Int8VNTR and 10-repeat of 3′VNTR are risk
alleles (Inoue-Murayama et al., 2002; Miller and Madras 2002; Hill et al., 2010),
expressional reduction of B5G10TC in cocaine abusers suggests two possibilities:
B5G10TC is sensitive to cocaine abuse or this haplotype is genomically and functionally
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modified in individuals with the liability for cocaine abuse. There is no experimental data on
the two Exon 15 SNPs rs6876890 and rs11564775 yet but MFOLD analysis shows that in
the rs6347 G allele background, order of free energy is 10TC (−1453.74 kcal/mol) < 10TT
(−1452.94 kcal/mol) < 10CT (−1448.91 kcal/mol), suggesting that TC of rs6876890 and
rs11564775 might contribute to greater stability of this main mRNA species. However, the
mechanism for the down-regulation merits further investigation also at an epigenetic level
(Hawi et al., 2010; Shumay et al., 2010). Other regions including the 5′ end and the 3′ end
represent risks and deserve further functional clarifications as well.
Variation of haplotype-dependence
Individual-dependent correlation between alleles and hDAT mRNA levels was observed for
both exonic markers rs6347 and 3′VNTR independently of drug phenotypes (Figure 3),
representing a flip-flop correlation. Two relevant questions are how the flip-flop correlation
could happen and what this means to association studies. Among other possibilities, one
potential answer to the first question is that the underlying regulatory regions lie in upstream
regions such as the promoter and have low LD with these markers. This possibility is
supported by the fact that the correlation between allelic ratio and overall mRNA levels is
weaker for 3′VNTR than for rs6347 (Figure 3c vs. d). Another possibility is that these
markers are functional but allelic expression varies among the individuals. No functional
study on rs6347 has been done. Since both rs6347 and 3′VNTR are exonic and the
polymorphisms may affect mRNA activity, we have carried out MFOLD modeling to see
whether the polymorphisms might influence mRNA secondary structure or stability. The
mRNA structures with the major alleles display lower free energy for greater stability than
ones with the minor alleles. In the background of 10 repeat of 3′VNTR, the molecule with G
(the major allele of rs6347) has a free energy of −1450.15 kcal/mol, comparing to −1448.91
kcal/mol in the molecule with A, or comparing to −1449.70 kcal/mol in the molecule with G
but 9-repeat. In other words, the variation from G into A in rs6347 increases the free energy
by 1.24 kcal/mol, 2.8-fold of the increase (0.45 kcal/mol) caused by the variation of 10-
repeat into 9-repeat in 3′VNTR. These modeling results suggest that rs6347 is more likely to
affect the mRNA stability than 3′VNTR. Consistent with this notion, the G allele that
confers higher structural stability tends to correlate with higher expression levels than A in
controls only (A/A-carriers had 30.2% reduction comparing to G/G-carriers, P = 0.0485 by
Mann-Whitney U tests) but 3′VNTR lacks such correlation tendency. Despite the
consistency between free energy modeling and experimental data, the small differences in
free energy may suggest that other factors have contributed to the 30.2% reduction and these
modeling data require future investigations for verification.
If expression variation of hDAT contributes to genetic etiologies of related brain disorders,
the flip-flop allelic expression indicates the importance of marker selection in association
study. Meanwhile, it is critical to continuously map the underlying genomic loci that may
serve the best markers.
CONCLUSIONS
hDAT has many regulatory haplotypes and its activity can be down-regulated in a haplotype-
and phenotype-dependent manner. Neither of the two most used markers, Int8VNTR and
3′VNTR, are correlated with the hDAT mRNA levels in the human midbrain. 5′VNTR may
represent a novel marker based on its positive correlation with the expression levels.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Seven hDAT markers typed in this study: location, frequency and linkage disequilibrium
(LD). (a) Schematic location of seven markers (*) and approximate LD (D′, boldface value
by Haploview, otherwise by SHEsis) for selected hDAT regions (horizontal bar). Underline,
exonic markers used in monitoring mRNA levels; double-arrowed horizontal line, selected
LD; exons in gray. (b) LD among seven hDAT markers. Upper panel: SHEsis; lower panels,
Haploview. Strong LD is observed for 3′ end and LD differences observed between controls
and cocaine abusers.
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Figure 2.
Identification of a cocaine abuse-related haplotype B5G10TC. (a) Down-regulation of hDAT
mRNA levels in B5G10TC-carriers. (b) hDAT mRNA levels in all subjects. (c) hDAT
mRNA levels in other-haplotype (non-B5G10TC)-carriers where P value by Mann–Whitney
U tests is 0.3704 (all P values two-tailed).
Zhou et al. Page 12
Addict Biol. Author manuscript; available in PMC 2015 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 3.
Correlation between 3′ markers (rs6347 in panels a and c or 3′VNTR in panels b and d) and
mRNA levels of hDAT in human ventral midbrain. Variable allele-dependence of hDAT
mRNA levels, based on rs6347 (18 subjects in panel a) and 3′VNTR (11 subjects in panel
b). Horizontal line, G/A or 10-repeat/9-repeat ratio = 1. Subject label: A for drug-free
control, B for cocaine abuser; underline, control-case pair (see Table 1); corresponding
haplotypes are statistically inferred and indicated on the right hand side. Data were obtained
from three independent experiments. ANOVA P values of < 0.0001 indicate significant
individual-dependence. Insert, representative BStop-PCR data. Correlation between allelic
ratio of rs6347 (c) or 3′VNTR (d) and overall levels of hDAT mRNA in human midbrain
tissues. rs6347 was carried by eight drug-free controls and ten cocaine abusers; 3′VNTR by
four drug-free controls and seven cocaine abusers. Vertical line, allelic ratio as 1. r2,
goodness of linear fit; P, significance of non-zero slope.
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Figure 4.
5′VNTR-based positive allelic correlation with hDAT expression in midbrain tissues from
drug-free controls (a, b) but not from cocaine abusers (c, d). Repeats: sum of both alleles.
Panels a and c, distribution of individuals; panels b and d, averages of mRNA levels where
r2, is goodness of linear fit and P, significance of non-zero slope.
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Table 1
Demographic information on the 36 subjects.
ID Drug1 Race2 Gender3 Age pH
A1 drug-free AA F 40 6.41
B1 cocaine AA F 34 6.42
A2 drug-free AA M 33 6.32
B2 cocaine AA M 35 6.53
A3 drug-free AA M 35 6.35
B3 cocaine AA M 35 6.70
A5 drug-free AA M 45 6.32
B5 cocaine AA M 46 6.57
A6 drug-free AA M 49 6.79
B6 cocaine AA M 49 6.40
A7 drug-free AA M 47 6.48
B7 cocaine AA M 52 6.47
A8 drug-free AA M 52 6.32
B8 cocaine AA M 52 6.30
10A drug-free AA F 45 6.24
10B cocaine AA F 42 6.26
11A drug-free AA F 51 6.46
11B cocaine AA F 52 6.30
12A drug-free AA M 47 6.60
12B cocaine AA M 51 6,65
13A drug-free AA M 56 6.67
13B cocaine AA M 57 6.70
15A drug-free AA M 34 6.62
15B cocaine AA M 34 6.40
16A drug-free AA M 45 6.43
16B cocaine AA M 45 6.90
19A drug-free AA F 47 6.62
19B cocaine AA F 50 6.30
20A drug-free AA M 53 6.31
20B cocaine AA M 59 6.60
21A drug-free AA M 51 6.70
21B cocaine AA M 54 6.60
22A drug-free AA M 66 6.74
22B cocaine AA M 64 6.70
23A drug-free AA M 46 6.78
23B cocaine AA M 52 6.60
1drug-free control; cocaine: cocaine abuser
2AA: African American (defined by medical legal records);
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3
F: female; M: male.
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